



#### CONTACTS

**Jordan Davis** or **Daniel Lubin**

Radius Ventures

212/897-7778

[jdavis@radiusventures.com](mailto:jdavis@radiusventures.com) or [dlubin@radiusventures.com](mailto:dlubin@radiusventures.com)

**Anthony Citrano**

fama PR

617/758-4140

[anthony@famapr.com](mailto:anthony@famapr.com)

#### **RADIUS VENTURES ADDS DR. GEORGE MILNE AS VENTURE PARTNER**

*Former EVP of Pfizer Global R&D Bolsters Radius' Life Sciences Expertise*

NEW YORK, NY—March 3, 2003—Radius Ventures ([www.RadiusVentures.com](http://www.RadiusVentures.com)), a New York-based venture capital firm focused on health and life science investments, today announced the addition of Dr. George Milne, recently retired EVP of Global Research and Development at Pfizer (NYSE: PFE) and a director on numerous boards including Mettler-Toledo, Charles River Labs, Athersys, and the New York Botanical Garden. Dr. Milne brings over three decades of pharmaceutical industry experience to the Radius team.

Dr. Milne joined Pfizer in 1970 and conducted both chemistry and pharmacology research until he was appointed director of Pfizer's Department of Immunology and Infectious Diseases in 1981. He became the department's executive director from 1984 to 1985 and was vice president of research and development from 1985 to 1988. He was appointed senior vice president in 1988. In 1993 he became president of Central Research and a senior vice president of Pfizer with global responsibility for human and veterinary medicine R&D. During his tenure as president, Dr. Milne led the unprecedented growth of the Research Division as evidenced by a five-fold increase in annual investment from \$493 million in 1992 to \$2.3 billion in 2000 and more than doubling of the scientific staff to over 8,000. Following the acquisition of Warner-Lambert in 2000 until his retirement, Dr. Milne assumed the role of executive vice president of Pfizer Global Research & Development and president of Worldwide Strategic & Operations Management. Dr. Milne received his B.S., Chemistry from Yale and a Ph.D. in Organic Chemistry from MIT.

"My many years in R&D were rewarding because I was constantly exposed to fresh new ideas, great people, and the opportunity to make a difference in healthcare and in the healthcare industry," said Dr. George Milne, venture partner at Radius Ventures. "By joining Radius Ventures and working directly with their high-quality portfolio companies and the founders of new enterprises, I am able to continue this exciting work while adding value to the companies and fund alike."

“Adding a world-class pharmaceutical executive of Dr. Milne’s caliber, with decades of experience, further solidifies Radius’ expertise in one of our core investment areas,” said Jordan Davis, co-founder and managing partner of Radius Ventures. “In addition to George’s superb understanding of the challenges of bringing new compounds through the clinical development cycle, he also has a unique sense of the needs and expectations of ‘Big Pharma’ with regard to structuring strategic alliances with small, innovative life sciences companies. Under George’s leadership, Pfizer grew their external alliance portfolio from an annual investment of \$27 million to over \$228 million. We are looking forward to putting this kind of experience and dedication to growth to work for Radius’ portfolio companies.”

Last month, Radius announced the closing of its second fund, Radius Venture Partners II, L.P. at \$73.5 million bringing the firm’s total capital under management to nearly \$100 million. Radius Ventures’ investments have included Amicas, BEI Medical Systems, Clinical Microsensors, Comprehensive Neurosciences, Nugen Technologies, and Zettacore.

### **About Radius Venture Partners**

Radius Ventures is a New York City-based venture capital firm focused on early-stage opportunities within the health and life sciences industry. Founded in 1997, Radius manages two funds with total committed capital of approximately \$100 million. The firm invests up to \$5 million in each of its portfolio companies and pursues a highly active investment style, providing substantial resources and direction to company management. Radius seeks opportunities across a broad spectrum including biotechnology and pharmaceuticals, medical devices and products, health and life sciences enterprise and application software, and healthcare services. On a selective basis, Radius considers later-stage health and life sciences investments where the firm can uniquely apply its industry and capital markets experience. Radius is licensed as a Small Business Investment Company (SBIC). For more information, visit: [www.RadiusVentures.com](http://www.RadiusVentures.com).